Northwest Biotherapeutics, Inc.

268 articles about Northwest Biotherapeutics, Inc.

• Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

  3/21/2024

  Northwest Biotherapeutics announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024.

• Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

  2/6/2024

  Northwest Biotherapeutics announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system.

• Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

  12/21/2023

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio") announced today that a Marketing Authorization Application (MAA) was submitted yesterday to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for DCVax®-L for glioblastoma brain cancer.

• Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

  11/22/2023

  Northwest Biotherapeutics provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.   

• Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

  10/13/2023

  Northwest Biotherapeutics provided an update about its progress toward submission of a Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

• Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

  9/12/2023

  Northwest Biotherapeutics announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board.

• Northwest Biotherapeutics Announces Completion of Prerequisites, and Plans for Submission of Marketing Authorization Application

  8/29/2023

  Northwest Biotherapeutics announces that it plans to submit a Marketing Authorization Application in the U.K., to the Medicines and Healthcare Products Regulatory Agency, for commercial approval of the Company's DCVax®-L treatment for glioblastoma.

• Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility

  3/20/2023

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio") and Advent BioServices jointly announce that a MIA license has been approved and issued by the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial manufacturing of cell therapy products at the GMP facility in Sawston, U.K.

• Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB

  3/11/2023

  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has no banking relationship with Silicon Valley Bank and no funds on deposit at SVB.

• Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023

  1/6/2023

  Northwest Biotherapeutics reported positive results of voting at the Annual Shareholders Meeting on December 30, 2022 , and discussion at the Meeting (which was publicly available) about achievements in 2022 and anticipated activities in 2023.

• Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma

  11/17/2022

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio") today reported that in its Phase III clinical trial both median survival and the "long tail" of extended survival were increased in both newly diagnosed and recurrent glioblastoma brain cancer patients treated with DCVax®-L.

• Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA

  8/23/2022

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tumor cancers, today announced that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the Company's Pediatric Investigation Plan (PIP).

• Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing at Sawston, UK Facility

  7/6/2022

  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that an application for license of the manufacturing facility in Sawston, UK for commercial manufacturing of cellular therapies has been submitted to the Medicines and Healthcare Products Regulatory Agency.

• Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program

  6/6/2022

  Northwest Biotherapeutics reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company's DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up.

• Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

  5/10/2022

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"),reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.

• Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

  5/4/2022

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.

• Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

  2/17/2022

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.

• Northwest Biotherapeutics Announces $15 Million Financing

  11/29/2021

  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's cash reserves above $20 million.

• Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

  10/28/2021

  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.

• UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

  5/12/2021

  Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency.